Two hundred twelve melanoma patients, including 38 prospective and 174 retrospective cases, were ABO and HL‐A typed, and the results were compared with those obtained in a sample of 562 healthy controls. The phenotype frequencies within the ABO system were identical in patients and controls. A lower frequency of HL‐A7 (significant at the 5% level) was observed in the melanoma patients. Furthermore, deviations from the controls were observed in the following subgroups of patients: a deficiency of HL‐A7 in the female patients (5% level); and a surplus of HL‐A1 (1% level) and W19 (5% level) in patients with chances of 5‐year corrected survival rates of 0–19% and 20–79(%, respectively. However, although statistically significant, the deviations should at present be considered to be fortuitous as roughly 200 comparisons were made. It is concluded that the investigation did not throw any light on the etiology of the disease or the prognosis of the patients.
Four new antigens of the second HL—A series are reported. They were established by means of lymphocytotoxic and platelet complement‐fixing antisera, and they behaved in population and family studies as determined by alleles at the second HL—A sublocus. It was found that three of them were parts of a previously assumed monofactorial antigen: SL. The antigen SL thus is heterogeneous, as also seems to be true of several other HL—A antigens. If all HL—A genetic determinants presently identified in our laboratories are taken into account, 18,145 different genotypes are possible. Implications of heterogeneous HL—A antigens for histocompatibility testing and matching are discussed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.